Abstract:Inherited genetic disorders are progressive in nature and lead to organ dysfunction or death in severe cases. At present, there are no permanent treatment options for >95% of inherited disorders. Different modes of inheritance, type of gene(s) involved, and population-based variations add further complexity to finding suitable cures for approximately 400 million patients worldwide. Gene therapy is a very promising molecular technique for the treatment of rare genetic disorders. Gene therapy functions on the basis of restoration, replacement, inhibition, and, most recently, editing of gene(s) to rescue the disease phenotype. Recent reports show that increasing numbers of gene therapy clinical trials are using viral vectors (64.2%) when compared with non-viral vectors. Rapid development of efficient viral vector systems like the adeno-associated virus (AAV) and lentivirus has significantly contributed to this progress. Notably, AAV-mediated gene therapy has shown high potential for genetic disease treatment as evident from recent clinical trials for the eye (NCT00999609), blood (NCT00979238), and neuro-muscular systems (NCT02122952). Safety and efficacy are the two most critical features required for vector(s) to qualify for pre-clinical and clinical trial approval. The process of clinical-grade vector production, evaluation, and approvals for gene therapy products requires significant technological development, knowledge enhancement, and large financial investments. Additionally, trained manpower is required to meet the demands for constant technical innovation. These factors together contribute towards exorbitant prices for every dose of a gene therapy product and thus pose a challenge for the gene therapy field. The Indian subcontinent has traditionally lagged behind North America, Europe, Japan, and others in gene therapy clinical trials due to factors like inadequate industrial-scientific infrastructure, lack of accessible and organized patient databases, low financial investments, etc. However, over the last decade, increasing awareness of rare diseases, and international approvals of gene therapies such as Luxturna, Zolgensma, Hemgenix, etc., have spurred gene therapy development in India as well. In view of these advances, this article outlines gene therapy research, regulatory processes, and the launch of gene therapy clinical trials in India in the context of major developments worldwide. We briefly describe ongoing gene therapy research across Indian organizations and the nascent gene therapy product manufacturing. Further, we highlight the various initiatives from the medical and patient community to avail rehabilitation and gene therapy options. We briefly discuss the roles of regulatory agencies and guidelines for gene therapy clinical trials in India. We anticipate that this concise review will highlight the promise of gene therapy for the large population of rare disease patients in India.

The translational gap for gene therapies in low- and middle-income countries

Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI)

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

Recent developments in gene therapy research in India

Improving access to gene therapy for rare diseases

Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders

Gene Therapy Advancements for Precision Cancer Treatment: Challenges and Opportunities in Sub-Saharan Africa – Nigeria Perspective

Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application

Successes and challenges in clinical gene therapy

Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications

Clinical and Translational Landscape of Viral Gene Therapies

Navigating equity in global access to genome therapy expanding access to potentially transformative therapies and benefiting those in need requires global policy changes

Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord

Riding the gene therapy wave: challenges and opportunities for rare disease patients and clinicians

Enhancing pediatric access to cell and gene therapies

Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update

Challenges for gene therapy in the financial sustainability of health systems: a scoping review

Reducing the costs of blockbuster gene and cell therapies in the Global South

Clinical development on the frontier: gene therapy for duchenne muscular dystrophy

Gene Therapy:the Present and Prospect

Somatic Gene Therapy: Ethics and Access